Aeovian Pharmaceuticals key facts
as of Oct 2026- Developer of biotechnology therapies intended to address inflammatory and degenerative diseases.
- Aeovian Pharmaceuticals is valued at approximately $172.0M as of Oct 2026, set at its later-stage round, Dec 2025; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $143.2M across 3 recorded rounds; the latest was Later Stage VC ($55.0M) in Nov 2025.
- Notable investors include FJ Labs, United States Department of War, TA Ventures, b2venture, Foresite Capital — 22 tracked in total.
- Aeovian Pharmaceuticals has filed 3 Form Ds with the SEC since 2019, most recently Dec 2025 ($55.0M sold to 13 investors).
- Status: Privately Held (backing).
Valued at $172.0M at its later-stage round, Dec 2025. Nothing has traded since.
- ·The complete investor list: 22 names
- ·Watch Aeovian Pharmaceuticals: the Monday email on marks, rounds and moves
Aeovian Pharmaceuticals funding rounds
3 roundsWho backs Aeovian Pharmaceuticals
22+Aeovian Pharmaceuticals valuation
Aeovian Pharmaceuticals was valued at $172 million at its later-stage round in Dec 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Aeovian Pharmaceuticals raised?
Aeovian Pharmaceuticals has raised $143 million across 3 recorded rounds since 2019. The largest was a $55 million later-stage round in Nov 2025.
Aeovian Pharmaceuticals has filed 3 Form Ds with the SEC since 2019, most recently in Dec 2025 ($55 million sold to 13 investors).
Aeovian Pharmaceuticals investors
22 investors are on record for Aeovian Pharmaceuticals, including FJ Labs, United States Department of War, TA Ventures and b2venture. By type, the record holds 6 venture capital firms and 2 family offices. The later-stage round in Nov 2025 drew 13 investors.
About Aeovian Pharmaceuticals
Developer of biotechnology therapies intended to address inflammatory and degenerative diseases. The company's platform utilizes small molecule therapeutics to target key cellular pathways involved in inflammation and disease progression, incorporating advanced drug design, precision targeting, and optimized pharmacokinetics, enabling the healthcare industry to develop more effective treatments with improved safety profiles for patients suffering from chronic and debilitating conditions.
- Sector
- Healthcare
- HQ
- Berkeley, CA, United States
- Founded
- 2012
- Employees
- 8
- Website
- aeovian.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.